Boston Scientific buys gene therapy company in series of acquisitions
This article was originally published in Clinica
Executive Summary
Two weeks after announcing its intention to pay $2.1 billion for catheter manufacturer, Schneider Worldwide, Boston Scientific has agreed to buy the development-stage company CardioGene Therapeutics, for an undisclosed amount.